我国科研人员将与丹麦制药公司联手研究心血管疾病恶化的机制,以协助推进有关疗法的研发。
新加坡科技研究局(A*STAR,简称新科研)发出的文告说,这项协议将重点研究射血分数正常的心力衰竭(Heart failure with preserved ejection fraction,HFpEF)。
Read the full article in Mandarin
here.
(Original article from Lianhe Zaobao
here.)
Tags:
;
;
;
;
News Article;
;
National Heart Centre Singapore;
;
Lianhe Zaobao;
;
;
;
;
Research
SOURCE: LIANHE ZAOBAO SINGAPORE PRESS HOLDINGS LIMITED, REPRODUCED WITH PERMISSION